Former Chief Medical Officer · CRISPR Therapeutics AG (CRSP)

Phuong Khanh Morrow

FY2023 is the first fiscal year CompBrief holds for Phuong Khanh Morrow as a named executive officer of CRISPR Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,160,174

Salary $527,900Stock awards $950,840

4th of 6 named executive officers at Crispr Therapeutics by FY2023 total.

6 named officers on file for CRISPR Therapeutics, FY2023

Phuong Khanh Morrow’s pay file — $29

  • 1 fiscal year of pay, line by line
  • CRSP’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRISPR Therapeutics’s whole pay program stands against its peers

  • CRISPR Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRSP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 9, 2024 (DEF 14A).

Free

Get Phuong Khanh Morrow’s full pay file as a PDF — free

More than this page: up to 10 years of Phuong’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Phuong Khanh Morrow compensation by year

CRISPR Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as CRISPR Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$527,900
Bonus$0
Stock awards$950,840
Option awards$1,668,234
Non-equity incentive$0
Pension and deferred compensation$0
All other$13,200
Total$3,160,174

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRISPR Therapeutics AG DEF 14A filed April 9, 2024, accession 0000950170-24-043025, and prior-year filings.

How this page was built: the CRISPR Therapeutics AG filed document, accession 0000950170-24-043025. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2024.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU27,750$1,128,038—
Option8,990—$61.65
Option90,000—$54.71

Per the Outstanding Equity Awards at Fiscal Year-End table in CRISPR Therapeutics AG's FY2022 proxy; value at the fiscal year-end close, as the company printed it.

CRISPR Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Samarth KulkarniChairman and Chief Executive Officer$12,322,196
Raju PrasadChief Financial Officer$5,718,566
James KasingerGeneral Counsel$3,510,398
Phuong Khanh Morrow · this pageFormer Chief Medical Officer$3,160,174
Rodger NovakFormer President and Chairman$555,065
Brendan SmithFormer Chief Financial Officer$114,750

The full CRISPR Therapeutics compensation record

free company brief

This page is one person within CRISPR Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRISPR Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Phuong Khanh Morrow's compensation dossier · One-time report. No refunds.